Knight Therapeutics Inc. (TSE:GUD) Director Purchases C$99,998.70 in Stock

Knight Therapeutics Inc. (TSE:GUDGet Rating) Director Samira Sakhia bought 19,455 shares of the business’s stock in a transaction on Monday, June 20th. The shares were acquired at an average price of C$5.14 per share, for a total transaction of C$99,998.70. Following the completion of the transaction, the director now owns 158,954 shares in the company, valued at approximately C$817,023.56.

Samira Sakhia also recently made the following trade(s):

  • On Wednesday, May 18th, Samira Sakhia bought 19,305 shares of Knight Therapeutics stock. The shares were acquired at an average price of C$5.18 per share, for a total transaction of C$99,999.90.

TSE GUD opened at C$5.11 on Thursday. The stock has a market cap of C$589.13 million and a price-to-earnings ratio of -92.91. Knight Therapeutics Inc. has a 52-week low of C$5.01 and a 52-week high of C$5.74. The business has a 50 day simple moving average of C$5.30 and a 200 day simple moving average of C$5.34. The company has a debt-to-equity ratio of 5.64, a quick ratio of 2.05 and a current ratio of 2.73.

Knight Therapeutics (TSE:GUDGet Rating) last issued its quarterly earnings results on Thursday, May 12th. The company reported C($0.02) earnings per share for the quarter, topping the consensus estimate of C($0.04) by C$0.02. The business had revenue of C$63.81 million for the quarter, compared to the consensus estimate of C$52.80 million. On average, analysts predict that Knight Therapeutics Inc. will post -0.02 EPS for the current year.

GUD has been the topic of a number of analyst reports. Canaccord Genuity Group cut their price target on shares of Knight Therapeutics from C$8.00 to C$7.00 in a research report on Friday, March 25th. National Bankshares cut their price target on shares of Knight Therapeutics from C$8.00 to C$7.50 and set an “outperform” rating on the stock in a research report on Friday, March 25th. National Bank Financial cut their price target on shares of Knight Therapeutics from C$8.00 to C$7.50 and set an “outperform” rating on the stock in a research report on Friday, March 25th. Raymond James set a C$7.50 price target on shares of Knight Therapeutics and gave the company an “outperform” rating in a research report on Friday, April 1st. Finally, Bloom Burton reissued a “buy” rating and set a C$6.70 target price on shares of Knight Therapeutics in a research note on Monday, March 28th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Knight Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of C$7.00.

About Knight Therapeutics (Get Rating)

Knight Therapeutics Inc, a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma.

See Also

Insider Buying and Selling by Quarter for Knight Therapeutics (TSE:GUD)

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.